Skip to main content
SpringerLink
Log in

Grading and Management of Graft-vs-Host Disease

  • Chapter
Allogeneic Stem Cell Transplantation

Part of the book series: Current Clinical Oncology ((CCO))

Abstract

Clinical graft-vs-host disease (GVHD) is a challenging area of study. Objective documentation of organ involvement is frequently not available, there is considerable interobserver variability in staging, and response criteria used are inconsistent between studies. Despite these shortcomings, there has been a clear trend of progress in the field, and patient survival has improved. Herein, we discuss recent developments in grading and analysis, and review the outcomes using new approaches to prevention or treatment of GVHD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  PubMed  CAS  Google Scholar 

  2. Thomas ED, Storb R, Clift RA, et al. Bone marrow transplantation. N Engl J Med 1975; 292: 895–902.

    Article  PubMed  CAS  Google Scholar 

  3. Gratwohl A, Hermans J, Apperley J, et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Blood 1995; 86: 813–818.

    PubMed  CAS  Google Scholar 

  4. Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997; 97: 855–864.

    Article  PubMed  CAS  Google Scholar 

  5. Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    PubMed  CAS  Google Scholar 

  6. Martin P, Nash R, Sanders J, et al. Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation. Bone Marrow Transplant 1998; 21: 273–279.

    Article  PubMed  CAS  Google Scholar 

  7. Elliott CJ, Sloane JP, Sanderson KV, et al. The histological diagnosis of cutaneous graft-verus-host disease: relationship of skin changes to marrow purging and other clinical variables. Histopathology 1987; 11: 145–155.

    Article  PubMed  CAS  Google Scholar 

  8. Martino R, Romero P, Subira M, et al. Comparison of the classic Glucksberg criteria and the IBMTR Severity Index for grading acute graft-versus-host disease following HLA-identical sibling stem cell transplantation. Bone Marrow Transplant 1999; 24: 283–287.

    Article  PubMed  CAS  Google Scholar 

  9. Cahn JY, CordonnierJM, Lee S, et al. Societe Francaise de Greffe de Moelle (SFGM) and Dana Farber Cancer Institute (DFCI) prospective multicenter evaluation of two acute graft versus host disease grading systems: a preliminary analysis of 607 patients. Blood 2000; 96: 397a.

    Google Scholar 

  10. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  PubMed  CAS  Google Scholar 

  11. Atkinson K, Horowitz MM, Gale RP, et al. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Bone Marrow Transplant 1989; 4: 247–254.

    PubMed  CAS  Google Scholar 

  12. Sullivan KM, Witherspoon RP, Storb R, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognsotic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988; 72: 546–554.

    PubMed  CAS  Google Scholar 

  13. Przepiorka D, Anderlini P, Saliba R, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001; 6: 1695–1700.

    Article  Google Scholar 

  14. Wingard JR, Piantadosi S, Vogelsang GB, et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 1989; 74: 1428–1435.

    PubMed  CAS  Google Scholar 

  15. Pavletic S, Tarantolo S, Lynch J, et al. Chronic graft-versus-host disease after allogeneic blood stem cell or bone marrow transplantation: factors determining onset and survival. Proc Am Soc Clin Oncol 1999: 18: A201.

    Google Scholar 

  16. Lee SJ, Klein JP, Barrett J, et al. Chornic graft-vs-host disease (cGVHD) severity score: effects on leukemia-free survival. Blood 2000; 96: 556a.

    Google Scholar 

  17. Akpek G, Zahurak ML, Piantadosi S, et al. Development of a prognostic model for grading chronic graftversus-host disease. Blood 2001; 97: 1219–1226.

    Article  PubMed  CAS  Google Scholar 

  18. Arora M, Wagner JE, Davies SM, et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chornic graft-versus-host disease. Biol Blood Marrow Transplant 2001; 7: 265–273.

    Article  PubMed  CAS  Google Scholar 

  19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  20. Pepe MS, Longton G, Pettinger M, Mori M, Fisher LD, Storb R. Summarizing data on survival, relapse, and chronic graft-versus-host disease after bone marrow transplantation: motivation for and description of new methods. Br J Haematol 1993; 83: 602–607.

    Article  PubMed  CAS  Google Scholar 

  21. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695–705.

    Article  PubMed  CAS  Google Scholar 

  22. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-verusu-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024–1030.

    PubMed  CAS  Google Scholar 

  23. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990; 76: 1464–1472.

    PubMed  CAS  Google Scholar 

  24. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991; 77: 1821–1828.

    PubMed  CAS  Google Scholar 

  25. Aschan J. Treatment of moderate to severe acute graft-versus-host diseae: a retrospective analysis. Bone Marrow Transplant 1994; 14: 601–607.

    PubMed  CAS  Google Scholar 

  26. Koc S, Leisenring W, Flowers ME, et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood 2000; 96: 3995–3996.

    PubMed  CAS  Google Scholar 

  27. Dreger P, Viehmann K, Steinmann J, et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T cell depletion strategies using different CD34+ selection systems or CAMPATH-1. Exp Hematol 1995; 23: 147–154.

    PubMed  CAS  Google Scholar 

  28. Stainer CJ, Miflin G, Anderson S, Davy B, McQuaker IG, Russell NH. A comparison of two different systems for CD34+ selection of autologous or allogeneic PBSC collections. JHematother 1998; 7: 375–383.

    Article  CAS  Google Scholar 

  29. Fritsch G, Schamer D, Froschl G, et al. Selection of CD34-positive blood cells for allogeneic transplantation: approaches to optimize CD34-cell recovery, purity, viability and T-cell depletion. Onkologie 2000; 23: 449–456.

    Article  PubMed  Google Scholar 

  30. Mavroudis DA, Read EJ, Molldrem J, et al. T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogeneic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia. Bone Marrow Transplant 1998; 21: 431–440.

    Article  PubMed  CAS  Google Scholar 

  31. Cornetta K Gharpure V, Mills B, et al. Rapid engraftment after allogeneic transplantation using CD34enriched marrow cells. Bone Marrow Transplant 1998; 21: 65–71.

    Article  PubMed  CAS  Google Scholar 

  32. Stoppa AM, Chabannon C, Faucher C, et al. Feasibility of CD34 selected allogeneic bone marrow transplantation (ABMT) followed after 3 months by prophylactic donor lymphocyte infusion (DLI) in hematologic malignancies. Blood 2000; 96: 790a.

    Google Scholar 

  33. Link H, Arseniev L, Bahre O, KadarJG, Diedrich H, Poliwoda H. Transplantation of allogeneic CD34+ blood cells. Blood 1996; 87: 4903–4909.

    PubMed  CAS  Google Scholar 

  34. Bensinger WI, Buckner CD, Shannon-Dorcy K, et al. Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy. Blood 1996; 88: 4132–4138.

    PubMed  CAS  Google Scholar 

  35. Urbano-Ispizua A, Rozman C, Martinez C, et al. Rapid engraftment without significant graft-versus-host disease after allogeneic transplantation of CD34+ selected cells from peripheral blood. Blood 1997;89:3967–3973.

    PubMed  CAS  Google Scholar 

  36. Finke J, Brugger W, Bertz H, et al. Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors. Bone Marrow Transplant 1996; 18: 1081–1086.

    PubMed  CAS  Google Scholar 

  37. Urbano-Ispizua A, Solano C, Brunet S, et al. Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic techniques. Apanish Group of Allo-PBT. Bone Marrow Transplant 1998; 22: 519–525.

    Article  PubMed  CAS  Google Scholar 

  38. Alegre A, Arranz R, Granda A, et al. Allogeneic peripheral blood stem cell transplantation (allo-PBSCT) with CD34 positive selection for advanced hemopathies. Blood 2000; 96: 336b.

    Google Scholar 

  39. Viret F, Chabannon C, Aurran-Schleinitz T, et al. Transplantation of allogeneic CD34+ blood cells in leukemia or lymphoma patients at high risk of GVHD. Bone Marrow Transplant 1999; 24: 225–227.

    Article  PubMed  CAS  Google Scholar 

  40. Waller EK, Langston AA, Bucur S, et al. Sequential CD34+ and CD3+ allogeneic cell transplants in patients with poor risk hematologic malignancies. Blood 2000; 96: 359b.

    Google Scholar 

  41. Bensinger W, Cornetta K, Carabasi M, et al. T cell depleted allogeneic PBSC transplantation using CD34+ cell selection. Blood 2000; 96: 199a.

    Google Scholar 

  42. Haddad N, Zuckerman T, Katz T, et al. Allogeneic BMT for CML using T-cell depletion and megadoses of CD34 cells; potential for reduced toxicity without loss of efficacy? Blood 2000; 96: 142a.

    Google Scholar 

  43. Martino R, Martin-Henao G, Sureda A, et al. Allogeneic peripheral blood stem cell transplantation with CD34+-cell selection and delayed T-cell add-back in adults. Results of a single center pilot study. Haematology 2000; 85: 1165–1171.

    CAS  Google Scholar 

  44. Beelen DW, Peceny R, Elmaagacli A, et al. Transplantation of highly purified HLA-identical sibling donor peripheral blood CD34+ cells without prophylactic post-transplant immunosuppression in adult patients with first chronic phase chronic myeloid leukemia: results of a phase II study. Bone Marrow Transplant 2000; 26: 823–829.

    Article  PubMed  CAS  Google Scholar 

  45. Urbano-Ispizua A, Rozman C, Pimentel P, et al. The number of donor CD3+ cells is the most important factor for graft failure after allogeneic transplantation of CD34+ selected cells from peripheral blood from HLAidentical siblings. Blood 2001; 97: 383–387.

    Article  PubMed  CAS  Google Scholar 

  46. Urbano-Ipsizua A, Pimental P, Solano C, et al. Predictive factors for graft versus host disease after allogeneic transplantation of CD34+ selected cells from peripheral blood (allo-PBT/CD34+) from HLA-identical siblings. Blood 2000; 96: 396a.

    Google Scholar 

  47. Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell-depleted haploidentical “three-loci” incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84: 3948–3955.

    PubMed  CAS  Google Scholar 

  48. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186–1193.

    Article  PubMed  CAS  Google Scholar 

  49. Kawano Y, Takaue Y, Watanabe A, et al. Partially mismatched pediatric transplants with allogeneic CD34+ blood cells from a related donor. Blood 1998; 92: 2123–3130.

    Google Scholar 

  50. Passweg JR, Kuhne T, Gregor M, et al. Increased stem cell dose, as obtained using currently available technology, may not be sufficient for engraftment of haploidentical stem cell transplants. Bone Marrow Transplant 2000; 26: 1033–1036.

    Article  PubMed  CAS  Google Scholar 

  51. Bunjes D, Duncker C, Wiesneth M, et al. CD34+ selected cells in mismatched stem cell transplantation: a single centre experience of haploidentical peripheral blood stem cell transplantation. Bone Marrow Transplant 2000;26(suppl 2): S9-S 11.

    Google Scholar 

  52. Handgretinger R, Klingebiel T, Lang P, et al. Megadose transplantation of purified peripheral blood CD34+ progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 2001; 27: 777–783.

    Article  PubMed  CAS  Google Scholar 

  53. McGuirk JP, Dix SP, Greenfield RJ, et al. Ex vivo T-cell depletion for graft versus host disease prophylaxis in related haplo-identical allogeneic stem cell transplant recipients. Blood 2000; 96: 362b.

    Google Scholar 

  54. Bacigalupo A, Mordini N, Pitto A, et al. Transplantation of HLA-mismatched CD34+ selected cells in patients with advanced malignancies: severe immunodeficiency and related complications. Br J Haematol 1997; 98: 760–766.

    Article  PubMed  CAS  Google Scholar 

  55. Kato S, Yabe H, Yasui M, et al. Allogeneic hematopoietic transplantation of CD34+ selected cells from an HLA haplo-identical related donor. A long-term follow-up of 135 patients and a comparison of stem cell source between the bone marrow and the peripheral blood. Bone Marrow Transplant 2000; 26: 1281–1290.

    Article  PubMed  CAS  Google Scholar 

  56. Lang P, Handgretinger R, Schlegel PG, et al. Transplantation of allogeneic purified peripheral CD34+ stem cells for nonmalignant diseases in children. Blood 2000; 96: 418a.

    Google Scholar 

  57. Briones J, Urbano-Ispizua A, Lawler M, et al. High frequency of donor chimerism after allogeneic transplantation of CD34+-selected peripheral blood cells. Exp Hematol 1998; 26: 415–420.

    PubMed  CAS  Google Scholar 

  58. Socie G, Cayuela JM, Raynal B, et al. Influence of CD34 cell selection on the incidence of mixed chimaerism and minimal residual disease after allgoeneic unrelated donor transplantation. Leukemia 1998; 12: 1440–1446.

    Article  PubMed  CAS  Google Scholar 

  59. Craddock C, Bardy P, Kreiter S, et al. Engraftment of T-cell-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen. Br J Haematol 2000; 111: 797–800.

    Article  PubMed  CAS  Google Scholar 

  60. Martinez C, Urbano-Ispizua A, Rozman C, et al. Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation: comparison of recipients of positive CD34+ selected grafts with recipients of unmanipulated grafts. Exp Hematol 1999; 27: 561–568.

    Article  PubMed  CAS  Google Scholar 

  61. Behringer D, Bertz H, Schmoor C, Berger C, Dwenger A, Finke J. Quantitative lymphocyte subset reconstitution after allogeneic hematopoietic transplantation from amtched related donors with CD34+ selected PBPC grafts unselected PBPC grafts or BM grafts. Bone Marrow Transplant 1999; 24: 295–302.

    Article  PubMed  CAS  Google Scholar 

  62. Knauf W, Fietz T, Schrezenmeier H, Thiel E. CD34 selected a11oPBSCT and adoptive immunotherapy. Bone Marrow Transplant 2000; 26 (Suppl 2): S2 - S5.

    Article  Google Scholar 

  63. Cavazzana-Calvo M, Hacein-Bey S, Schindler J, et al. Donor T lymphocyte infusion following ex vivo depletion of donor anti-host reactivity by an anti-CD25 immunotoxin(IT). Preliminary results of a Phase U II trial. Blood 2000; 96: 477a.

    Google Scholar 

  64. Moscardo F, Sanz GF, de la Rubia J, et al. Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34+ positive selection. Bone Marrow Transplant 2001; 27: 983–988.

    Article  PubMed  CAS  Google Scholar 

  65. McSweeney PA, Niederweiser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patietns with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390–3400.

    Article  PubMed  CAS  Google Scholar 

  66. Sandmaier BM, Maloney DG, Hegenbart U, et al. Nonmyeloablative conditioning for HLA-identical related allografts for hematologic malignancies. Blood 2000; 96: 479a.

    Google Scholar 

  67. Aivado M, Huenerlituerkoglu A, et al. High incidence of acute GVHD after allogeneic blood stem cell transplantation following minimal intensive conditioning. Blood 2000; 96: 784a.

    Google Scholar 

  68. Bornhauser M, Schuler U, Porksen G, et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 1999; 67: 499–504.

    Article  PubMed  CAS  Google Scholar 

  69. Kiehl MG, Armstrong V, BasaraN, et al. Intravenous mycophenoate mofetil plus prednisolone and cyclospirne in the prophylaxis of GVHD after stem cell transplantation. Blood 1999; 94 (Suppl 1): 153a.

    Google Scholar 

  70. Basara N, Blau WI, Kiehl MG, et al. Mycophenolate mofetil for the prophylaxis of acute GVHD in HLAmismatched bone marrow transplant patients. Clin Transplant 2000; 14: 121–126.

    Article  PubMed  CAS  Google Scholar 

  71. Hale G, Jacobs P, Wood L, et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 2000; 26: 69–76.

    Article  PubMed  CAS  Google Scholar 

  72. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-2H prevents graft-versus-host disease following nonmyeloabltaive stem cell transplantation. Blood 2000; 96: 2419 2425.

    Google Scholar 

  73. Peggs KS, Mahendra P, Milligan DW, et al. Non-myeloablative transplantation using matched unrelated donors - in vivo campath-1H limits graft versus host disease. Blood 2000; 96: 841a.

    Google Scholar 

  74. Rizzieri DA, Long GD, Vredenburgh JJ, et al. Chimerism mediated immunotherapy using campath T cell depleted peripheral blood progenitor cells (PBPC) with nonablative therapy provides reliable durable allogeneic engraftment. Blood 2000; 96: 521a.

    Google Scholar 

  75. Potter MN, Grace SC, Teehan C, et al. Campath 1 H “in the bag” is an effective method of GVHD prevention in allogeneic stem cell transplantation. Blood 2000; 96: 476a.

    Google Scholar 

  76. Durrant S, Mollee P, Morton AJ, Irving I. Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-versus-host disease developing during cyclosporine prophylaxis. Br J Haematol 2001; 113: 217–223.

    Article  PubMed  CAS  Google Scholar 

  77. Furlong T, Storb R, Anasetti C, et al. Clinical outcome after conversion to FK506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-assiciated toxicities. Bone Marrow Transplant 2000; 26: 985–991.

    Article  PubMed  CAS  Google Scholar 

  78. Koehler MT, Howrie D, Mirro J, et al. FK506 (tacrolimus) in the treatment of steroid-resistant acute graftversus-host disease in children undergoing bone marrow transplantation. Bone Marrow Transplant 1995; 15: 895–899.

    Article  PubMed  CAS  Google Scholar 

  79. Kanamaru A, Takemoto Y, Kakishita E, et al. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis with cyclosporin and/or other immunosuppressants. Bone Marrow Transplant 1995; 15: 885–889.

    PubMed  CAS  Google Scholar 

  80. Ihlan O, Celebi H, Arat O, et al. Treatment of acute and chronic graft versus host disease with mycophenolate mofetil. Blood 1999; 94 (Suppl 1): 368b.

    Google Scholar 

  81. Abhyankar S, Godder K, Christiansen N, et al. Treatment of resistant acute and chronic graft versus host disease with mycophenolate mofetil. Blood 1998; 92 (Suppl 1): 340b.

    Google Scholar 

  82. Basara N, Kiehl MG, Blau W, et al. Mycophenolate mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience. Transplant Proc 2001; 33: 2121 2123.

    Google Scholar 

  83. Ozsahin H, Tuchschmid P, Lauener R, et al. Blockade of acute grade IV skin and eye graft-versus-host disease by anti-interleukin-2 receptor monoclonal antibody in genoidentical bone amrrow transplantation setting. Turk J Pediatr 1998; 40: 231–235.

    PubMed  CAS  Google Scholar 

  84. Przepiorka D, Kernan NA Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95: 83–89.

    PubMed  CAS  Google Scholar 

  85. Willenbacher W, Basara N, Blau IW, Fauser AA, Kiehl MG. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol 2001; 112: 820–823.

    Article  PubMed  CAS  Google Scholar 

  86. Pasquini R, Moreira VA, de Medeiros CR, Bonfim C Basiliximab (BaMab) - a selective interleukin-2 receptor (IL-2R) antagonist - as therapy for refractory acute graft versus host disease (a-GVHD) following bone marrow transplantation. Bone Marrow Transplant 2000; 96: 177a.

    Google Scholar 

  87. Kobbe G, Schneider P, Rohr U, et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse anti-TNF alpha antibody. Bone Marrow Transplant 2001; 28: 47–49.

    Article  PubMed  CAS  Google Scholar 

  88. Andolina M, Rabusin M, Maximova N, Di Leo G. Etanercept in graft-versus-host disease. Bone Marrow Transplant 2000; 26: 929.

    Article  PubMed  CAS  Google Scholar 

  89. Lim SH, McWhannell A, Vora AJ, Boughton BJ. Successful treatment with thalidomide of acute graft-versushost disease after bone-marrow transplantation. Lancet 1988; 1: 117.

    Article  PubMed  CAS  Google Scholar 

  90. Ringden O, Aschan J, Westerberg L. Thalidomide for severe acute graft-versus-host disease. Lancet 1988; 2: 568.

    Article  PubMed  CAS  Google Scholar 

  91. McCarthy DM, KanferE, TaylorJ, Barrett AJ. Thalidomide for graft-versus-host disease. Lancet 1988; 2: 1135.

    Article  PubMed  CAS  Google Scholar 

  92. Mehta P, Kedar A, Graham-Pole J, Skoda-Smith S, Wingard JR. Thalidomide in children undergoing bone marrow transplantation: series at a single institution and review of the literature. Pediatrics 1999; 103: e44 - e48.

    Article  PubMed  CAS  Google Scholar 

  93. Nagler A, Menachem Y, Ilan Y. Amelioration of steroid-resistant chronic graft-versus-host mediated liver disease via tacrolimus treatment. J Hematother Stem Cell Res 2001; 10: 411–417.

    Article  PubMed  CAS  Google Scholar 

  94. Redei I, Langston AA, Cherry JK, Allen A, Waller EK. Salvage therapy with mycophenolate mofetil (MMF) for ptients with severe chronic GVHD. Blood 1999; 94 (Suppl 1): 159a.

    Google Scholar 

  95. Roberts T, Koc Y, Sprague K, et al. Mycophenolate mofetil (MMF) for the treatment of chronic graft versus host disease (cGVHD) of the liver. Blood 1999; 94 (Suppl 1): 159a.

    Google Scholar 

  96. Pallotta-Filho RS, Barbosa JAL, Macedo MCMA, et al. The use of mycophenolate mofetil in the treatment of refractory chronic graft versus host disease. Blood 1998; 92 (Suppl 1): 346b.

    Google Scholar 

  97. Busca A, Saroglia EM, Lanino E, et al. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation. Bone Marrow Transplant 2000; 25: 1067–1071.

    Article  PubMed  CAS  Google Scholar 

  98. Mookerjee B, Altomonte V, Vogelsang G. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant 1999; 24: 517–520.

    Article  PubMed  CAS  Google Scholar 

  99. Ratanatharathorn V, Carson E, Reynolds C, et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in apatient with chronic graft-versus-host disease. Ann Intern Med 2000; 15: 275–279.

    Article  Google Scholar 

  100. Szabolcs P, Reese M, Yancey K, Hall RP, Kurtzberg J. Combination treatment of bullous skin GVHD and anti-CD20 and anti-CD25 antibodies. Blood 2000; 96: 350b.

    Google Scholar 

  101. Arora M, Wagner JE, Davies SM, et al. Randomized clinical trial of thalidomide, cyclosporine and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001; 7: 265–273.

    Article  PubMed  CAS  Google Scholar 

  102. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. NEngl JMed 1992; 326: 1055–1058.

    Article  CAS  Google Scholar 

  103. Cole CH, Rogers PC, Pritchard S, Phillips G, Chan KW. Thalidomide in the management of chronic graft-versushost disease in children following bone marrow transplantation. Bone Marrow Transplant 1994; 14: 937–942.

    PubMed  CAS  Google Scholar 

  104. Saurat J-H, Camenzind M, Helg C, Chapuis B. Thalidomide for graft-versus-host disease after bone marrow transplantation. Lancet 1988; 1: 359.

    Article  PubMed  CAS  Google Scholar 

  105. Heney D, Lewis IJ, Bailey CC. Thalidomide for chronic graft-versus-host disease in children. Lancet 1988; 2: 1317.

    Article  PubMed  CAS  Google Scholar 

  106. Heney D, Norfolk DR, Wheeldon J, Bailey CC, Lewis IJ Barnard DL. Thalidomide treatment for chronic graft-versus-host disease. Br J Haematol 1991; 78: 23–27.

    Article  PubMed  CAS  Google Scholar 

  107. Parker PM, Chao N, Nademanee A, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995; 86: 3604–3609.

    PubMed  CAS  Google Scholar 

  108. Rovelli A, Arrigo C, Nesi F, et al. The role of thalidomide in the treatment of refractory chronic graft-versushost disease following bone marrow transplantation in children. Bone Marrow Transplant 1998; 21: 577–581.

    Article  PubMed  CAS  Google Scholar 

  109. Browne PV, Weisdorf DJ, DeFor T, et al. Response to thalidomide therapy in refractory chonic graft-versushost disease. Bone Marrow Transplant 2000: 26: 865–869.

    Article  PubMed  CAS  Google Scholar 

  110. van de Poel MH, Pasman PC, Schouten HC. The use of thalidomide in chronic refractory graft versus host disease. Neth J Med 2001; 59: 45–49.

    Article  PubMed  Google Scholar 

  111. Gilman AL, Chan KW, Mogul A, et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2000: 6: 327–334.

    Article  PubMed  CAS  Google Scholar 

  112. Hiraoka AF for the Japanese FK506 BMT Study Group. Results of a phase III study on prophylactic use of FK506 for acute GVHD compared with cyclosporine in allogeneic bone marrow transplantation. Blood 1997; 90: 561a.

    Google Scholar 

  113. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLAidentical sibling bone marrow transplantation. Blood 1998; 92: 2303 2314.

    Google Scholar 

  114. Nash RA, Antin JH, Karanes C, et al. A phase III study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062–2068.

    PubMed  CAS  Google Scholar 

  115. Przepiorka D. Prevention of acute graft-versus-host disease. In: Ball ED, Lister J, Law P, eds. Hematopoietic Stem Cell Therapy. Churchill Livingstone, Philadelphia, PA, 2000, pp. 452–469.

    Google Scholar 

  116. Przepiorka D, Devine SM, Fay JW, Uberti JP, Wingard JR. Practical considerations in the use of tacrolimus for allogeneic marrow transplantation. Bone Marrow Transplant 1999; 24: 1053–1056.

    Article  PubMed  CAS  Google Scholar 

  117. Narwani RR, Reddy V, Wingard JR, et al. Topical tacrolimus may be useful for skin manifestations of acute and chronic graft-versus-host disease (GVHD) after bone marrow transplantation (BMT). Blood 1999; 94 (Suppl 1): 370b.

    Google Scholar 

  118. Carnevale-Schianca F, Martin P, Sullivan K, et al. Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2000; 6: 613–620.

    Article  PubMed  CAS  Google Scholar 

  119. Yu C, Seidel K, Nash RA, et al. Synergism between mycophenolate mofetil and cyclosporine in preventing greaft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 1998; 91: 2581 2587.

    Google Scholar 

  120. Jenke A, Renner U, Richte M, et al. Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. Clin Transplant 2001; 15: 176–184.

    Article  PubMed  CAS  Google Scholar 

  121. Kiehl MG, Shipkova M, Basara N, et al. Mycophenolate mofetil in stem cell transplant patients in relation to plasma level of active metabolite. Clin Biochem 2000; 33: 203–208.

    Article  PubMed  CAS  Google Scholar 

  122. Anasetti C, Hansen JA, Waldmann TA, et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 1994; 84: 1320–1327.

    PubMed  CAS  Google Scholar 

  123. Anasetti C, Lin A, Nademanee A, et al. A Phase I /III randomized, double-blind, placebo-controlled multicenter trial of humanized anti-Tac for prevention of acute graft-versus-host disease (GVHD) in recipients of marrow transplants from unrelated donors. Blood 1995; 86 (Suppl 1): 621a.

    Google Scholar 

  124. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993; 82: 807–812.

    PubMed  CAS  Google Scholar 

  125. Chakrabarti S, Kottaridis P, Ogormon P, et al. High incidence of early and late CMV infection and delayed immune reconstitution after allogeneic transplants with nonmyeloablative conditioning using Campath (antiCD52 antibody). Blood 2000; 96: 586a.

    Google Scholar 

  126. Raefsky EL, Gascon P, Gratwohl A, et al. Biological and immunological characterization of ATG and ALG. Blood 1986; 68: 712–719.

    PubMed  CAS  Google Scholar 

  127. Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/ antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 1995; 59: 1194–1200.

    PubMed  CAS  Google Scholar 

  128. Ourahma S, Talon D, Barrou B, et al. A prospective study on efficacy and tolerance of antithymocyte globulin Fresenius versus thymoglobuline Merieux after renal transplantation. Transplant Proc 1997; 29: 2427.

    Google Scholar 

  129. Norrby J, Olaus son M. Arandomized clinical trial using ATG Fresenius or ATG Merieux as induction therapy in kidney transplantation. Transplant Proc 1997; 29: 3135–3136.

    Article  PubMed  CAS  Google Scholar 

  130. Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, Phase III clinical trial of thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998; 66: 29–37.

    Article  PubMed  CAS  Google Scholar 

  131. Baurmann H, Revillard JP, Bonnefoy-Berard N, Schwerdtfeger R. Potent effects of ATG used as part of the conditioning in matched unrealted donor (MUD) transplantation. Blood 1998; 92 (Suppl 1): 290a.

    Google Scholar 

  132. Eiermann TH, Freitag S, Cortes-Dericks L, Sahm H, Zander AR. Jurkat cell-reactive anti-thymocyte globulin assessed ex vivo by flow cytomtery persists three weeks in ciruclation. J Hematother Stem Cell Res 2001; 10: 395–390.

    Article  Google Scholar 

  133. Toren A, Ilan Y, Or R, Kapelushnik J, Nagler A. Impaired liver function tests in patients treated with antithymocyte globulin: implication for liver transplantation. Med Oncol 1997; 14: 125–129.

    Article  PubMed  CAS  Google Scholar 

  134. Remberger M, Svahn B-M, Hentschke P, Lôfgren C, Ringden O. Effect on cytokine release and graft-versushost disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24: 823–830.

    Article  PubMed  CAS  Google Scholar 

  135. Storb R, Etzioni R, Anasetti C, et al. Cyclophophamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994; 84: 941–949.

    PubMed  CAS  Google Scholar 

  136. Holler E, Ledderose G, Knabe H, et al. ATG serotherapy during pretransplant conditioning in unrelated donor BMT: dose dependent modulation of GVHD. Bone Marrow Transplant 1998; 21 (Suppl 1): S30.

    Google Scholar 

  137. Kanda Y, Mineishi S, Nakai K, Saito T, Tanosaki R, Takue Y. Frequent detection of rising cytomegalovirus antigenemia after allogeneic stem cell transplantation following a regimen containing antithymocyte globulin. Blood 2001; 97: 3676, 3677.

    Google Scholar 

  138. Kroger N, Zabelina T, Kruger W, et al. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin. Br Haematol 2001; 113: 1060–1071.

    Article  CAS  Google Scholar 

  139. Hsu B, May R, Carrum G, Krance R, Przepiorka D. Use of antithymocyte globulin for treatment of acute graftversus-host disease: an international practice survey. Bone Marrow Transplant 2001; 10: 945–950.

    Article  Google Scholar 

  140. Boughton BJ, Sheehan TM, Wood J, et al. High-performance liquid chromatography assay of plasma thalidomide: stabilization of specimens and determination of a tentative therapeutic range for chronic graft-versushost disease. Ann Clin Biochem 1995; 32: 79–83.

    PubMed  CAS  Google Scholar 

  141. Schlossberg H, Klumpp T, Sabol P, Herman J, Mangan K. Severe cutaneous ulceration following treatment with thalidomide for GVHD. Bone Marrow Transplant 2001; 27: 229, 230.

    Google Scholar 

  142. Chao NJ, Parker PM, Niland JC, et al. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs-host disease. Biol Blood Marrow Transplant 1996; 2: 86–92.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Donna Przepiorka MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Allogeneic Transplant Program, Ireland Cancer Center, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA

    Mary J. Laughlin MD

  2. Blood and Marrow Transplant Program, Ireland Cancer Center, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA

    Hillard M. Lazarus MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Przepiorka, D. (2003). Grading and Management of Graft-vs-Host Disease. In: Laughlin, M.J., Lazarus, H.M. (eds) Allogeneic Stem Cell Transplantation. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-333-0_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-333-0_16

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-4481-1

  • Online ISBN: 978-1-59259-333-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation